Trevi Therapeutics, Inc. (TRVI) — Financial statements
Income statement, balance sheet, and cash flow for Trevi Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 33↓15.0% | 39↑66.3% | 24↑19.4% | 20↓13.7% | 23 | |
| General & Administrative Expenses | 16↑30.5% | 12↑18.6% | 10↑1.7% | 10↑6.1% | 9 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 16↑30.5% | 12↑18.6% | 10↑1.7% | 10↑6.1% | 9 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 49↓4.3% | 52↑51.9% | 34↑13.4% | 30↓7.9% | 32 | |
| Total Costs & Expenses | 49↓4.3% | 52↑51.9% | 34↑13.4% | 30↓7.9% | 32 | |
| Operating Results | ||||||
| Operating Income | -49↑4.3% | -52↓51.9% | -34↓13.4% | -30↑7.9% | -32 | |
| Depreciation & Amortization | 0.14↓2.0% | 0.15↑19.5% | 0.12↑186.0% | 0.04↓14.0% | 0.05 | |
| EBITDA | -43↑10.7% | -48↓67.2% | -29↓2.1% | -28↑14.5% | -33 | |
| EBIT | -43↑10.7% | -48↓67.0% | -29↓2.4% | -28↑14.5% | -33 | |
| Interest & Other Income | ||||||
| Net Interest Income | 7↑81.7% | 4↓17.4% | 4↑353.9% | 0.96↑180.5% | -1 | |
| Interest Income | 7↑81.5% | 4↓24.1% | 5↑172.9% | 2↑17300.0% | 0.01 | |
| Interest Expense | 0.00↓100.0% | 0.00↓99.0% | 0.39↓49.9% | 0.78↓35.1% | 1 | |
| Non-Operating Income | -7↓81.3% | -4↑31.2% | -5↓177.2% | -2↓765.0% | 0.28 | |
| Other Income / Expenses | 7↑81.6% | 4↓25.8% | 5↑571.2% | 0.72↑148.4% | -1 | |
| Income Before Tax | -43↑10.7% | -48↓64.8% | -29↑0.3% | -29↑14.1% | -34 | |
| Income Tax Expense | -0.06↓113.3% | -0.03↑6.3% | -0.03↑11.1% | -0.04↓71.4% | -0.02 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -43↑10.8% | -48↓64.8% | -29↑0.3% | -29↑14.1% | -34 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -43↑10.8% | -48↓64.8% | -29↑0.3% | -29↑14.1% | -34 | |
| Bottom-Line Net Income | -43↑10.8% | -48↓64.8% | -29↑0.3% | -29↑14.1% | -34 | |
| EPS (Basic) | -0.29↑38.3% | -0.47↓62.1% | -0.29↑35.6% | -0.45↑69.8% | -1.49 | |
| EPS (Diluted) | -0.29↑38.3% | -0.47↓62.1% | -0.29↑35.6% | -0.45↑69.8% | -1.49 | |
| Weighted Average Shares | 145↑43.6% | 101↑2.0% | 99↑53.4% | 65↑182.6% | 23 | |
| Weighted Average Diluted Shares | 145↑43.6% | 101↑2.0% | 99↑53.4% | 65↑182.6% | 23 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.